The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator
Open accessAbstract
We have carried out a cell-based screen aimed at discovering small molecules that activate p53 and have the potential to decrease tumor growth. Here, we describe one of our hit compounds, tenovin-1, along with a more water-soluble analog, tenovin-6. Via a yeast genetic screen, biochemical assays, and target validation studies in mammalian cells, we show that tenovins act through inhibition of the protein-deacetylating activities of SirT1 and SirT2, two important members of the sirtuin family. Tenovins are active on mammalian cells at one-digit micromolar concentrations and decrease tumor growth in vivo as single agents. This underscores the utility of these compounds as biological tools for the study of sirtuin function as well as their potential therapeutic interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Self-citationNegative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Sirtuins in mammals: insights into their biological function
Michan, S., & Sinclair, D. (2007) · Biochemical Journal · doi:10.1042/bj20070140 · Cited by 1,718
The Human Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase
North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., & Verdin, E. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00038-8 · Cited by 1,536
Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins
Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409
Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction
Haigis, M. C., & Guarente, L. P. (2006) · Genes & Development · doi:10.1101/gad.1467506 · Cited by 1,295 · cited 3×
“Mammals have seven sirtuin homologs (sirtuins, SirT1-7) with diverse NAD+-dependent enzymatic activities (protein deacetylase and/or ADP-ribosyl transferase), cellular locations, and substrates (Haigis and Guarente, 2006; Michan and Sinclair, 2007).”
BackgroundStott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice
Cheng, H.-L., Mostoslavsky, R., Saito, S., Manis, J. P., Gu, Y., Patel, P., Bronson, R., Appella, E., Alt, F. W., & Chua, K. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934713100 · Cited by 1,095 · cited 2×
“Accordingly, cells derived from SirT1 deficient mice and cells treated with siRNAs against SirT1 show high levels of hyperacetylated p53 (Cheng et al., 2003; Ford et al., 2005), and as shown here (Figure 6A), a dominant-negative SirT1 (Luo et al.”
Background
Cited by
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
“The tenovins, on the other hand, are small molecule p53 activators, which have been shown to decrease tumour growth in vivo [81].”
BackgroundMammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
“Several SIRT1 inhibitors such as sirtinol (250), suramin (280), tenovins (197), 3,2=,3=,4=-tetrahydroxychalcone (174), EX-527 (240), and cambinol (154) have been demonstrated to induce senescence in preclinical tumor models (323).”
BackgroundCancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Self-citationThe sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
The Role of Sirtuins in Antioxidant and Redox Signaling
Singh, C. K., Chhabra, G., Ndiaye, M. A., Garcia-Peterson, L. M., Mack, N. J., & Ahmad, N. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7290 · Cited by 812
Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice
Wang, R.-H., Sengupta, K., Li, C., Kim, H.-S., Cao, L., Xiao, C., Kim, S., Xu, X., Zheng, Y., Chilton, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.001 · Cited by 769
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Self-citationThe p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
p53 post-translational modification: deregulated in tumorigenesis
Dai, C., & Gu, W. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523
The multifaceted functions of sirtuins in cancer
Chalkiadaki, A., & Guarente, L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3985 · Cited by 496
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target
Zhang, J., Xiang, H., Liu, J., Chen, Y., He, R.-R., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.45922 · Cited by 503
Posttranslational Modification of p53: Cooperative Integrators of Function
Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 483
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
Sirtuin activators and inhibitors: Promises, achievements, and challenges
Dai, H., Sinclair, D. A., Ellis, J. L., & Steegborn, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.004 · Cited by 463
“Examples are the acylthioureas tenovin-1 and tenovin-6 (Lain et al., 2008) and the benzothiazol AC-93253 (Zhang et al.”
BackgroundHow does SIRT1 affect metabolism, senescence and cancer?
Brooks, C. L., & Gu, W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2562 · Cited by 428
Sirtuins — novel therapeutic targets to treat age-associated diseases
Lavu, S., Boss, O., Elliott, P. J., & Lambert, P. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2665 · Cited by 426
Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T. L., Chen, W., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.020 · Cited by 410
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer
Liu, T., Liu, P. Y., & Marshall, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3365 · Cited by 384
Sirtuin functions and modulation: from chemistry to the clinic
Carafa, V., Rotili, D., Forgione, M., Cuomo, F., Serretiello, E., Hailu, G. S., Jarho, E., Lahtela-Kakkonen, M., Mai, A., & Altucci, L. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0224-3 · Cited by 387
The Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
Sirtuin activators and inhibitors
Villalba, J. M., & Alcaín, F. J. (2012) · BioFactors · doi:10.1002/biof.1032 · Cited by 352
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
SIRT1 and p53, effect on cancer, senescence and beyond
Yi, J., & Luo, J. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.002 · Cited by 340
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
p53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
SIRT1, Is It a Tumor Promoter or Tumor Suppressor?
Deng, C.-X. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.147 · Cited by 321
Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming
Ong, A. L. C., & Ramasamy, T. S. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.004 · Cited by 301
Tatone, C., Di Emidio, G., Barbonetti, A., Carta, G., Luciano, A. M., Falone, S., & Amicarelli, F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy003 · Cited by 294
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & Müller, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 291
Menssen, A., Hydbring, P., Kapelle, K., Vervoorts, J., Diebold, J., Lüscher, B., Larsson, L.-G., & Hermeking, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105304109 · Cited by 275
Acetylation site specificities of lysine deacetylase inhibitors in human cells
Schölz, C., Weinert, B. T., Wagner, S. A., Beli, P., Miyake, Y., Qi, J., Jensen, L. J., Streicher, W., McCarthy, A. R., Westwood, N. J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3130 · Cited by 275
Self-citationSalermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
Lara, E., Mai, A., Calvanese, V, Altucci, L., Lopez-Nieva, P., Martinez-Chantar, M. L., Varela-Rey, M., Rotili, D., Nebbioso, A., Ropero, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.436 · Cited by 259
Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism
Gomes, P., Fleming Outeiro, T., & Cavadas, C. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.001 · Cited by 255
p53, ROS and senescence in the control of aging
Vigneron, A., & Vousden, K. H. (2010) · Aging · doi:10.18632/aging.100189 · Cited by 221
“Taken together there is good evidence that acetylation of p53 promotes sensecence and apoptosis, so inhibitors of the deacetylation enzymes might be useful drugs for the reactivation of these p53 responses for cancer therapy [29].”
BackgroundBrooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186
Activation of Stress Response Gene SIRT1 by BCR-ABL Promotes Leukemogenesis
Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Bhatia, R., & Chen, W. (2012) · Blood · doi:10.1182/blood-2011-06-361691 · Cited by 182
Phenformin as prophylaxis and therapy in breast cancer xenografts
Appleyard, M. V. C. L., Murray, K. E., Coates, P. J., Wullschleger, S., Bray, S. E., Kernohan, N. M., Fleming, S., Alessi, D. R., & Thompson, A. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.56 · Cited by 108
Self-citationNew insights into p53 activation
Brooks, C. L., & Gu, W. (2010) · Cell Research · doi:10.1038/cr.2010.53 · Cited by 102
Towards an understanding of the role of p53 in adrenocortical carcinogenesis
Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76
Role of p53 circuitry in tumorigenesis: A brief review
Niazi, S., Purohit, M., & Niazi, J. H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.099 · Cited by 65
Hua, W.-K., Qi, J., Cai, Q., Carnahan, E., Ayala Ramirez, M., Li, L., Marcucci, G., & Kuo, Y.-H. (2017) · Blood · doi:10.1182/blood-2017-03-771386 · Cited by 57
Sirtuins, a key regulator of ageing and age-related neurodegenerative diseases
Bhatt, V., & Tiwari, A. K. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2057849 · Cited by 28
Metadata
- Authors
- Lain, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K. E., Baker, L., Thompson, A., Mathers, J., Holland, S. J., Stark, M. J. R., Pass, G., Woods, J., Lane, D. P., & Westwood, N. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 13
- Issue
- 5
- Pages
- 454-463
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2140513990
- Cited by
- 522
- References
- 50
- FWCI
- 15.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.